Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Bristol-Myers Squibb Company's (NYSE:BMY) high institutional ownership speaks for itself as stock continues to impress, up 5.7% over last week
Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...
Wolfe starts Bristol Myers at Peer Perform, sees potential comeback story
Wolfe Research initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. The firm said there maybe a comeback story with Bristol, ...
Bristol Myers initiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Alexandria Hammond initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. Published first on TheFly ...
Hosted on MSN2d
Leerink Partners Upgrades Bristol-Myers Squibb (BMY)
Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from ...
Bristol-Myers upgraded at Leerink after AbbVie setback
Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript)
Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...
Buy, Sell, Or Hold BMY Stock?
This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...
What's Going On With Bristol-Myers Squibb Shares Monday?
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...
bovnews3d
Analysts Predict a $55 Target for Bristol-Myers Squibb Co (BMY) Stock—What Could Drive It There?
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $54.14 which represents a decrease of $-0.57 or -1.04% from the prior close of $54.71. The stock opened at $54.7 and ...